Yuk Ting Ma

Research output

Research output per year 2003 2011 2017 2018 2019 2020 2021 2023 2023

• 40 Article
• 5 Abstract
• 3 Review article

Research output per year

Research output per year

Search results

• 2023

  Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

  Rannikko, J. H., Verlingue, L., De miguel, M., Pasanen, A., Robbrecht, D., Skytta, T., Iivanainen, S., Shetty, S., Ma, Y. T., Graham, D. M., Arora, S. P., Jaakkola, P., Yap, C., Xiang, Y., Mandelin, J., Karvonen, M. K., Jalkanen, J., Karaman, S., Koivunen, J. P., Minchom, A., & 2 othersHollmén, M. & Bono, P., 19 Dec 2023, In: Cell Reports Medicine. 4, 12, 101307.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Macrophage Activation 100%
  • Neoplasms 28%
  • Interferons 26%
  • Biliary Tract Neoplasms 20%
  • Macrophages 20%
  11 Downloads (Pure)

• Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

  Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., Al-Mukhtar, A., Dickson, E., Graham, J., Jiao, L., Wasan, H. S., Tait, I. S., Prachalias, A., Ross, P., Valle, J. W., O'Reilly, D. A., & 15 othersAl-Sarireh, B., Gwynne, S., Ahmed, I., Connolly, K., Yim, K-L., Cunningham, D., Armstrong, T., Archer, C., Roberts, K., Ma, Y. T., Springfeld, C., Tjaden, C., Hackert, T., Büchler, M. W. & Neoptolemos, J. P., Feb 2023, In: The Lancet Gastroenterology & Hepatology. 8, 2, p. 157-168 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Capecitabine 100%
  • gemcitabine 88%
  • Chemoradiotherapy 84%
  • Pancreatic Neoplasms 75%
  • Neoadjuvant Therapy 43%
  19 Downloads (Pure)

• Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  Lawson, A., Kamarajah, S. K., Parente, A., Pufal, K., Sundareyan, R., Pawlik, T. M., Ma, Y. T., Shah, T., Kharkhanis, S., Dasari, B. V. M. & Sahin, I. (ed.), 13 Jun 2023, In: Cancers. 15, 12, 11 p., 3166.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  File

  • Hepatocellular Carcinoma 100%
  • Meta-Analysis 92%
  • Systematic Reviews 91%
  • Randomized Controlled Trials 52%
  • Survival 51%
  57 Downloads (Pure)

• Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma

  Mosconi, C., O’Rourke, J., Kloeckner, R., Sturm, L., Golfieri, R., Celsa, C., Fateen, W., Odisio, B. C., Garanzini, E. M., Peck-Radosavljevic, M., Borghi, A., Ma, Y. T., Stoehr, F., Bettinger, D., Giuffrida, P., Aithal, G. P., Lin, Y-M., Spreafico, C., Giampalma, E., Johnson, P., & 1 othersCucchetti, A., Apr 2023, In: Cardiovascular and Interventional Radiology. 46, 4, p. 449-459 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Textbooks 100%
  • Hepatocellular Carcinoma 66%
  • Risk Adjustment 23%
  • Patient Readmission 10%
  • Survival 10%
• 2022

  Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

  BILCAP study group, 20 Jun 2022, In: Journal of Clinical Oncology . 40, 18, p. 2048-2057 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Capecitabine 100%
  • Biliary Tract Neoplasms 56%
  • Survival 29%
  • Observation 28%
  • Standard of Care 25%

• Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

  Löffler, M. W., Gori, S., Izzo, F., Mayer-Mokler, A., Ascierto, P. A., Königsrainer, A., Ma, Y. T., Sangro, B., Francque, S., Vonghia, L., Inno, A., Avallone, A., Ludwig, J., Alcoba, D. D., Flohr, C., Aslan, K., Mendrzyk, R., Schuster, H., Borrelli, M., Valmori, D., & 15 othersChaumette, T., Heidenreich, R., Gouttefangeas, C., Forlani, G., Tagliamonte, M., Fusco, C., Penta, R., Iñarrairaegui, M., Gnad-Vogt, U., Reinhardt, C., Weinschenk, T., Accolla, R. S., Singh-Jasuja, H., Rammensee, H-G. & Buonaguro, L., 15 Jun 2022, In: Clinical Cancer Research. 28, 12, p. 2555-2566 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Cancer Vaccines 100%
  • Multicenter Studies 71%
  • Hepatocellular Carcinoma 66%
  • Peptides 31%
  • HLA-A*24:02 antigen 30%
• 2021

  Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma

  Razak, R. A., Fletcher, P., Kunene, V. & Ma, Y. T., 28 Feb 2021, In: Journal of Clinical Gastroenterology. 55, 2, p. 169-173 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Sorafenib 100%
  • Gastric Acid 94%
  • Hepatocellular Carcinoma 65%
  • Progression-Free Survival 44%
  • Survival 27%
  83 Downloads (Pure)

• Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit

  Childs, A., Zakeri, N., Ma, Y. T., O’Rourke, J., Ross, P., Hashem, E., Hubner, R. A., Hockenhull, K., Iwuji, C., Khan, S., Palmer, D. H., Connor, J., Swinson, D., Darby, S., Braconi, C., Roques, T., Yu, D., Luong, T. V. & Meyer, T., 9 Nov 2021, In: British Journal of Cancer. 125, 10, p. 1350-1355 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Hepatocellular Carcinoma 100%
  • Biopsy 75%
  • Liver Diseases 62%
  • Sorafenib 61%
  • Cholangiocarcinoma 57%

• Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

  Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., Anthoney, A., Maraveyas, A., Iveson, T., Waters, J. S., Hobbs, C., Barber, S., Ryder, W. D., Ramage, J., Davies, L. M., Bridgewater, J. A., & 1 othersValle, J. W., May 2021, In: The Lancet Oncology. 22, 5, p. 690-701 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Biliary Tract Neoplasms 100%
  • Leucovorin 84%
  • Oxaliplatin 83%
  • Fluorouracil 67%
  • Randomized Controlled Trials 47%

• Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II clinical trial

  Virtakoivu, R., Rannikko, J. H., Viitala, M., Vaura, F., Takeda, A., Lönnberg, T., Koivunen, J., Jaakkola, P., Pasanen, A., Shetty, S., Jonge, M. J. A. D., Robbrecht, D., Ma, Y. T., Skyttä, T., Minchom, A., Jalkanen, S., Karvonen, M. K., Mandelin, J., Bono, P. & Hollmen, M., 2 Jun 2021, In: Clinical Cancer Research. 27, 15, p. 4205-4220

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Phase II Clinical Trials 100%
  • Clinical Trials, Phase I 99%
  • Lymphocyte Activation 87%
  • Down-Regulation 57%
  • Macrophages 41%
  151 Downloads (Pure)

• The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study

  Sagar, V. M., Herring, K., Curbishley, S., Hodson, J., Fletcher, P., Karkhanis, S., Mehrzad, H., Punia, P., Shah, T., Shetty, S. & Ma, Y. T., 23 Nov 2021, In: OncoTarget. 12, 24, p. 2338-2350 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Prothrombin 100%
  • Vitamin K 98%
  • Hepatocellular Carcinoma 68%
  • Cohort Studies 58%
  • Biomarkers 55%
  69 Downloads (Pure)

• The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study

  Johnson, P. J., Dhanaraj, S., Berhane, S., Bonnett, L. & Ma, Y. T., 31 Aug 2021, In: British Journal of Cancer. 125, 5, p. 714-716 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Hepatocellular Carcinoma 100%
  • Neutrophils 97%
  • Lymphocytes 85%
  • Prospective Studies 79%
  • Liver Diseases 34%
  103 Downloads (Pure)

• Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

  Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., Meyer, T., Huang, K-W., Plummer, R., Chee, C. E., Spalding, D., Pai, M., Khan, S., Pinato, D. J., Sharma, R., Basu, B., & 11 othersPalmer, D., Ma, Y-T., Evans, J., Habib, R., Martirosyan, A., Elasri, N., Reynaud, A., Rossi, J. J., Cobbold, M., Habib, N. A. & Gabrilovich, D. I., 1 Nov 2021, In: Clinical Cancer Research. 27, 21, p. 5961-5978 18 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • CCAAT-Enhancer-Binding Protein-alpha 100%
  • Myeloid Cells 70%
  • Up-Regulation 50%
  • Myeloid-Derived Suppressor Cells 34%
  • Neoplasms 22%
  27 Downloads (Pure)
• 2020

  MTL-CEBPA, a Small Activating RNA Therapeutic Up-Regulating C/EBP-α, in Patients With Advanced Liver Cancer: A First-In-Human, Multi-Centre, Open-Label, Phase I Trial

  Ma, Y. T., May 2020, In: Clinical Cancer Research.

  Research output: Contribution to journal › Article › peer-review

• Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study

  Kalisvaart, M., Broadhurst, D., Marcon, F., Pande, R., Schlegel, A., Sutcliffe, R., Marudanayagam, R., Mirza, D., Chatzizacharias, N., Abradelo, M., Muiesan, P., Isaac, J., Ma, Y. T., Mcconville, C. & Roberts, K., 8 Feb 2020, In: HPB : the official journal of the International Hepato Pancreato Biliary Association. 22, 9, p. 1240-1249

  Research output: Contribution to journal › Article › peer-review

  • Pancreaticoduodenectomy 100%
  • Pancreatic Neoplasms 80%
  • Systematic Reviews 62%
  • Retrospective Studies 56%
  • Superior Mesenteric Artery 56%
  6 Citations (Scopus)

• Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

  Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., Lwuji, C., Wasan, H., Scott-brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., & 14 othersMachin, A., Dayim, A., Mcadam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I. & Palmer, D. H., 9 Jun 2020, In: British Journal of Cancer. 122, 12, p. 1760–1768 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • 130-nm albumin-bound paclitaxel 100%
  • gemcitabine 72%
  • Adenocarcinoma 50%
  • Progression-Free Survival 48%
  • Confidence Intervals 19%
  3 Citations (Scopus)

  127 Downloads (Pure)

• TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial

  Palmer, D. H., Valle, J. W., Ting Ma, Y., Faluyi, O., Neoptolemos, J. P., Jensen Gjertsen, T., Iversen, B., Amund Eriksen, J., Møller, A., Aksnes, A., Miller, R. & Dueland, S., 31 Mar 2020, In: British Journal of Cancer. 122, 7, p. 971–977 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • gemcitabine 100%
  • Granulocyte-Macrophage Colony-Stimulating Factor 94%
  • Pancreas 76%
  • Adenocarcinoma 70%
  • Disease-Free Survival 50%
  4 Citations (Scopus)

  132 Downloads (Pure)

• Treatment strategies for the optimal management of locally advanced pancreatic adenocarcinoma with curative intent: A systematic review.

  Ma, Y. T., 2020, In: Pancreas.

  Research output: Contribution to journal › Article › peer-review

  1 Citation (Scopus)
• 2019

  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

  BILCAP study group, Primrose, J. N., Fox, R. P., Palmer, D. H., Malik, H. Z., Prasad, R., Mirza, D., Anthony, A., Corrie, P., Falk, S., Finch-Jones, M., Wasan, H., Ross, P., Wall, L., Wadsley, J., Evans, J. T. R., Stocken, D., Praseedom, R., Ma, Y. T., Davidson, B., & 9 othersNeoptolemos, J. P., Iveson, T., Raftery, J., Zhu, S., Cunningham, D., Garden, O. J., Stubbs, C., Valle, J. W. & Bridgewater, J., May 2019, In: The Lancet Oncology. 20, 5, p. 663-673 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Biliary Tract Neoplasms 100%
  • Capecitabine 88%
  • Observation 50%
  • Survival 20%
  • Intention to Treat Analysis 8%
  243 Citations (Scopus)

• Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver

  Dasari, B. V. M. & Ma, Y. T., 12 Aug 2019, (E-pub ahead of print) In: HPB : the official journal of the International Hepato Pancreato Biliary Association.

  Research output: Contribution to journal › Article › peer-review

  • Hepatocellular Carcinoma 100%
  • Survival 68%
  • Liver 64%
  • Databases 18%
  • Neoplasms 15%
  3 Citations (Scopus)

• Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.

  Ahsan Javed, M. & Ma, Y. T., Jan 2019, In: Pancreatology. 19, 1, p. 97-104

  Research output: Contribution to journal › Article › peer-review

  • gemcitabine 100%
  • Adenocarcinoma 70%
  • Drug Therapy 52%
  • Survival 22%
  • 130-nm albumin-bound paclitaxel 15%
  20 Citations (Scopus)

• Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

  Ma, Y. T., Nov 2019, In: JAMA Surgery.

  Research output: Contribution to journal › Article › peer-review

  37 Citations (Scopus)
• 2018

  A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of Nintedanib vs. Sorafenib in European patients with advanced hepatocellular carcinoma

  Palmer, D. H., Ma, Y., Peck-Radosavljevic, M., Ross, P., Graham, J., Fartoux, L., Deptala, A., Studeny, M., Schnell, D., Hocke, J., Loembe, A-B. & Meyer, T., 22 Mar 2018, In: British Journal of Cancer. 118, p. 1162-1168 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • nintedanib 100%
  • Sorafenib 77%
  • Hepatocellular Carcinoma 50%
  • Pharmacokinetics 47%
  • Maximum Tolerated Dose 36%
  9 Citations (Scopus)

  224 Downloads (Pure)

• Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort

  Afshar, M., Fletcher, P., Bardoli, A., Ma, Y. & Punia, P., 30 Mar 2018, In: OncoTarget. 9, 24, p. 16988–16995 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Sorafenib 100%
  • Hepatocellular Carcinoma 65%
  • Neutrophils 63%
  • Lymphocytes 56%
  • Survival 45%
  5 Citations (Scopus)

  319 Downloads (Pure)

• Phase II studies with Refametinib or Refametinib plus Sorafenib in patients with RAS-mutated Hepatocellular Carcinoma

  Lim, H. Y., Merle, P., Weiss, K-H., Yau, T. CC., Ross, P., Blanc, J-F., Mazzaferro, V., Ma, Y., Yen, C-J., Kocsis, J., Choo, S. P., Sukeepaisarnjaroen, W., Gérolami, R., Dufour, J-F., Gane, E. J., Ryoo, B-Y., Peck-Radosavljevic, M., Dao, T., Yeo, W., Lamlertthon, W., & 7 othersThongsawat, S., Teufel, M., Roth, K., Reis, D., Childs, B. H., Krissel, H. & Llovet, J. M., 27 Jun 2018, (E-pub ahead of print) In: Clinical Cancer Research.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 100%
  • Sorafenib 59%
  • Hepatocellular Carcinoma 38%
  • Circulating Tumor DNA 34%
  • Mutation 10%
  26 Citations (Scopus)

  169 Downloads (Pure)

• The impact of transarterial chemoembolization induced complications on outcomes after liver transplantation: A propensity-matched study

  Pinter Carvalheiro da Silva Boteon, A., Longatto Boteon, Y., Vinuela, E. F., Derosas, C., Mergental, H., Isaac, J. R., Muiesan, P., Mehzard, H., Ma, Y., Shah, T., Mirza, D. F. & Perera, M. T. P. R., May 2018, In: Clinical transplantation. 32, 5, 10 p., e13255.

  Research output: Contribution to journal › Article › peer-review

  • Liver Transplantation 100%
  • Tissue Donors 86%
  • Cholecystitis 45%
  • Propensity Score 39%
  • Hepatectomy 39%
  2 Citations (Scopus)
• 2017

  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

  Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., Darby, S., Meyer, T., Gillmore, R., Anthoney, A., Lind, P., Glimelius, B., Falk, S., Izbicki, J. R., Middleton, G., Cummins, S., & 15 othersRoss, P. J., Wasan, H., McDonald, A., Crosby, T., Ma, Y., Patel, K., Sherriff, D., Soomal, R., Borg, D., Sothi, S., Hammel, P., Hackert, T., Jackson, R., Büchler, M. W. & European Study Group for Pancreatic Cancer, 11 Mar 2017, In: The Lancet. 389, 10073, p. 1011–1024

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Capecitabine 100%
  • gemcitabine 88%
  • Pancreatic Neoplasms 75%
  • Survival 13%
  • Random Allocation 11%
  771 Citations (Scopus)

  119 Downloads (Pure)

• Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature

  Atkin, C., Earwaker, P., Pallan, A., Shetty, S., Punia, P. & Ma, Y., 14 Feb 2017, In: BMC Gastroenterology. 17, 30.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Sorafenib 100%
  • Chronic Hepatitis C 85%
  • Hepatocellular Carcinoma 65%
  • Virus Diseases 59%
  • Hepacivirus 37%
  140 Downloads (Pure)

• Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

  Edeline, J., Blanc, J-F., Campillo-Gimenez, B., Ma, Y., King, J., Faluyi, O., Mathurin, J., Ghazi, S., Palmer, D. H. & Meyer, T., Nov 2017, In: European Journal of Cancer. 86, p. 135-142 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Sorafenib 100%
  • Hepatocellular Carcinoma 65%
  • Survival 22%
  • Bilirubin 15%
  • Albumins 13%
  11 Citations (Scopus)

• Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

  Meyer, T., Fox, R., Ma, Y., Ross, P., James, M., Sturgess, R., Stubbs, C., Stocken, D., Wall, L., Watkinson, A., Hacking, N., Evans, J., Collins, P., Hubner, R., Cunningham, D., Primrose, J., Johnson, P. & Palmer, D., Aug 2017, In: The Lancet Gastroenterology & Hepatology. 2, 8, p. 565–575

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Sorafenib 100%
  • Hepatocellular Carcinoma 65%
  • Placebos 56%
  • Progression-Free Survival 23%
  • Random Allocation 9%
  164 Citations (Scopus)

  178 Downloads (Pure)

• Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.

  Ma, Y., Leonard, S., Gordon, N., Anderton, J., James, C., Huen, D., Woodman, C. & Palmer, D. H., 8 Sept 2017, In: OncoTarget. 8, 38, p. 63635–63645 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  File

  • Haploidy 100%
  • Pancreatic Neoplasms 75%
  • Genome 53%
  • entinostat 51%
  • Deoxycytidine Kinase 49%
  1 Citation (Scopus)

  148 Downloads (Pure)
• 2016

  A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma

  Edeline, J., Blanc, J-F., Johnson, P., Campillo-Gimenez, B., Ross, P., Ma, Y., King, J., Hubner, R. A., Sumpter, K., Darby, S., Evans, J., Iwuji, C., Swinson, D., Collins, P., Patel, K., Muazzam, I., Palmer, D. H. & Meyer, T., Dec 2016, In: Liver International. 36, 12, p. 1821-1828 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sorafenib 100%
  • Bilirubin 79%
  • Albumins 69%
  • Hepatocellular Carcinoma 65%
  • Child 35%
  52 Citations (Scopus)
• 2015

  Developments in cancer vaccines for hepatocellular carcinoma

  Buonaguro, L., HEPAVAC Consortium, Ma, Y. & Adams, D., 21 Jun 2015, In: Cancer Immunology Immunotherapy. 65, 93.

  Research output: Contribution to journal › Article › peer-review

  • Cancer Vaccines 100%
  • Hepatocellular Carcinoma 66%
  • Phase II Clinical Trials 16%
  • Clinical Trials, Phase I 16%
  • Immunotherapy 12%
  32 Citations (Scopus)
• 2013

  Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom

  Palmer, D. H., Hussain, S. A., Smith, A. J., Hargreaves, S., Ma, Y., Hull, D., Johnson, P. J. & Ross, P. J., 20 Aug 2013, In: British Journal of Cancer. 109, 4, p. 888-90 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Sorafenib 100%
  • Hepatocellular Carcinoma 65%
  • Liver Diseases 19%
  • Northern Ireland 15%
  • Wales 13%
  16 Citations (Scopus)
• 2012

  Impact of restricting access to high-cost medications for hepatocellular carcinoma

  Ma, Y. T. & Palmer, D. H., 2012, In: Expert Review of Pharmacoeconomics & Outcomes Research. 12, 4, p. 465-73 9 p.

  Research output: Contribution to journal › Article › peer-review

  • medication 100%
  • Hepatocellular Carcinoma 94%
  • Clinical Trials 81%
  • Costs and Cost Analysis 72%
  • Sorafenib 71%
  4 Citations (Scopus)
• 2011

  Biology of germ cell tumors.

  Ma, Y., Cullen, M. & Hussain, S., 1 Jun 2011, In: Hematology/oncology clinics of North America. 25, 3, p. 457-71 15 p.

  Research output: Contribution to journal › Article

  • Germ Cell and Embryonal Neoplasms 100%
  • Testicular Neoplasms 32%
  • Neoplasms 27%
  • Molecular Biology 22%
  • Phenotype 16%
  7 Citations (Scopus)

• Evolution of systemic therapy for metastatic colorectal cancer

  Geh, J. & Ma, Y., 1 Aug 2011, In: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 13, 8, p. 852-4 3 p.

  Research output: Contribution to journal › Review article
  1 Citation (Scopus)

• Metastatic serous carcinoma of the testis: a case report and review of the literature

  Ma, Y., Chaudhri, S. & Cullen, M., 1 Jan 2011, In: Case reports in oncology. 4, 1, p. 246-9 4 p.

  Research output: Contribution to journal › Article

  Open Access

  • Testis 100%
  • Carcinoma 74%
  • Testicular Germ Cell Tumor 38%
  • Neoplasms 36%

• Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study.

  Ma, Y., Collins, S., Young, L., Murray, P. & Woodman, C., 26 Apr 2011, In: British Journal of Cancer. 104, 9, p. 1500-4 5 p.

  Research output: Contribution to journal › Article

  • Methylation 100%
  • Epigenomics 96%
  • Longitudinal Studies 91%
  • Epithelium 84%
  • Smoking 79%
  35 Citations (Scopus)
• 2010

  Human papillomavirus-induced methylation of RARB

  Ma, Y., Leonard, S., Murray, P., Roberts, S. & Woodman, C., 1 Jan 2010, p. Abstract B127.

  Research output: Contribution to conference (unpublished) › Abstract

• Smoking-induced p16 methylation in young women

  Ma, Y., Collins, S., Young, L., Murray, P. & Woodman, C., 1 Oct 2010, p. Abstract B48.

  Research output: Contribution to conference (unpublished) › Abstract
• 2008

  Biology of testicular germ cell tumors.

  Hussain, S., Ma, Y., Palmer, D., Hutton, P. & Cullen, M., 1 Oct 2008, In: Expert Review of Anticancer Therapy. 8, 10, p. 1659-73 15 p.

  Research output: Contribution to journal › Article

  • Testicular Germ Cell Tumor 100%
  • Germ Cells 53%
  • Germ Cell and Embryonal Neoplasms 42%
  • Neoplasms 23%
  • Drug Therapy 21%
  16 Citations (Scopus)

• Management of metastatic germ cell tumors.

  Hussain, S., Ma, Y. & Cullen, M., 1 May 2008, In: Expert Review of Anticancer Therapy. 8, 5, p. 771-84 14 p.

  Research output: Contribution to journal › Article

  • Germ Cell and Embryonal Neoplasms 100%
  • Testicular Neoplasms 32%
  • Bleomycin 32%
  • Etoposide 30%
  • Platinum 29%
  18 Citations (Scopus)
• 2007

  Smoking-induced epigenetic changes in young women

  Ma, Y., Collins, S., Young, L., Murray, P. & Woodman, C., 1 Jan 2007.

  Research output: Contribution to conference (unpublished) › Abstract
• 2006

  Case report: primary subcutaneous sacrococcygeal ependymoma: a case report and review of the literature

  Ma, Y., Ramachandra, P. & Spooner, D., 1 May 2006, In: British Journal of Radiology. 79, 941, p. 445-7 3 p.

  Research output: Contribution to journal › Review article

  • Ependymoma 100%
  • Pilonidal Sinus 77%
  • Lymph 56%
  • Neoplasm Metastasis 47%
  • Sacrococcygeal Region 38%
  27 Citations (Scopus)

• Identification of epigenetically inactivated tumour suppressor genes in cervical neoplasia using a genome wide assessment of both changes in promoter methylation and gene expression

  Ma, Y., Maloney, S., Wei, W., Arrand, J., Murray, P. & Woodman, C., 1 Jan 2006.

  Research output: Contribution to conference (unpublished) › Abstract
• 2004

  Outcome of parathyroidectomy for primary hyperparathyroidism in 249 consecutive patients

  Ma, Y., Toogood, A., Campbell, D., Ready, A., Heath, DA. & Gittoes, N., 1 Jan 2004, p. 9. 1 p.

  Research output: Contribution to conference (unpublished) › Abstract
• 2003

  Facial flushing and localised Castleman's disease: An extension of the POEMS syndrome phenotype

  Ma, Y., Weatherby, SJ., Rao, D., Winer, J., Craddock, C. & Williams, A., 1 Feb 2003, In: Journal of Internal Medicine. 253, 2, p. 247-248 2 p.

  Research output: Contribution to journal › Article
  1 Citation (Scopus)